596
Participants
Start Date
April 19, 2006
Primary Completion Date
July 30, 2020
Study Completion Date
January 19, 2022
PF-02341066
Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
Rifampin
600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
Itraconazole
Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
Peter MacCallum Cancer Centre, Melbourne
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center: Breast and Imaging Center, New York
Memorial Sloan-Kettering Cancer Center, New York
UPMC Hillman Cancer Center, Pittsburgh
Henry-Joyce Cancer Clinic, Nashville
Vanderbilt Eye Institute, Nashville
The James Cancer Hospital and Solove Research Institute, Columbus
Ohio State Eye and Ear Institute, Columbus
The Ohio State University Martha Morehouse Medical Plaza, Columbus
Karmanos Cancer Institute, Detroit
Kresge Eye Institute, Detroit
University of Chicago, Chicago
University of Colorado Hospital/ Anschutz Cancer Pavilion, Aurora
University of Colorado Hospital, Aurora
University of Colorado, Aurora
University of California, Irvine Medical Center, Orange
Massachusetts General Hospital, Boston
Ophthalmic Consultants of Boston Inc., Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Center, Boston
Joslin Beetham Eye Institute, Boston
UNC Hospitals, Chapel Hill
The University of Vermont Medical Center, Burlington
The University of Vermont Cancer Center, Burlington
Aichi cancer center central hospital, Nagoya
Hyogo Cancer Center, Akashi
Kindai University Hospital, Sayama
Seoul National University Hospital, Seoul
Lead Sponsor
Pfizer
INDUSTRY